SCHEMBL12401411

SCHEMBL12401411

CC(C)(C)C(=O)[C@@H](NC(=O)OC1CCC1)C(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.37
NPC1 O15118 1/20 0.37
HTT P42858 1/20 0.37
RAB9A P51151 1/20 0.37
TSHR P16473 2/20 0.36
ALDH1A1 P00352 1/20 0.36
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C19 P33261 1/20 0.36
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
MEN1 O00255 1/20 0.33
CYP1A2 P05177 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
FAAH O00519 1/20 0.31
MGLL Q99685 1/20 0.31
IDO1 P14902 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8243464 0.97 EPHX1 (0.44) EPHX1SMN1; SMN2NPC1HTTRAB9A
SCHEMBL12401415 0.97 EPHX1 (0.44) EPHX1SMN1; SMN2NPC1HTTRAB9A
SCHEMBL12401422 0.95 EPHX1 (0.46) EPHX1SMN1; SMN2NPC1HTTRAB9A
SCHEMBL14441686 0.95 EPHX1 (0.46) EPHX1SMN1; SMN2NPC1HTTRAB9A
SCHEMBL12401407 0.95 EPHX1 (0.46) EPHX1SMN1; SMN2NPC1HTTRAB9A
SCHEMBL12401420 0.93 EPHX1 (0.35) EPHX1SMN1; SMN2NPC1HTTRAB9A
SCHEMBL12401256 0.86 CNR2 (0.34) EPHX1SMN1; SMN2NPC1HTTRAB9A
SCHEMBL8250180 0.85 EPHX1 (0.41) EPHX1SMN1; SMN2NPC1HTTRAB9A
SCHEMBL15219814 0.85 EPHX1 (0.41) EPHX1SMN1; SMN2NPC1HTTRAB9A
SCHEMBL12401418 0.83 EPHX1 (0.41) EPHX1SMN1; SMN2NPC1HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372873-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-02-12 US disclosed
US-20110182856-A1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-28 US disclosed
US-7964624-B1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110182856-A1 INHIBITORS OF SERINE PROTEASES PRSS1, SPINT2, PRSS2 EPHX1 1623/4885SMN1; SMN2 2156/4885NPC1 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.